以CD28为基础的CD19嵌合抗原受体修饰T细胞治疗儿童及年轻成人B细胞急性淋巴细胞白血病的长期缓解参数
该研究报告37例接受自体CD19 CAR-T细胞治疗的儿童及年轻成人B细胞急性淋巴细胞白血病患者的长期结局,完全缓解率86%,3年无事件生存率41%、总生存率56%,淋巴清除前骨髓原始细胞>5%及第28天PCR MRD阳性与不良结局相关。
要点
- 完全缓解率86%,其中71%为PCR MRD阴性、14%为流式MRD阴性、14%为PCR MRD阳性。
- 中位随访3年,中位无事件生存17个月,中位总生存未达到,3年无事件生存率41%、总生存率56%。
- 淋巴清除前骨髓原始细胞>5%者无事件生存较差,第28天PCR MRD阳性者均复发。
核心结论
- 淋巴清除前疾病负荷和CAR-T细胞治疗后分子MRD阴性是CD19 CAR-T细胞治疗B细胞急性淋巴细胞白血病长期结局的预测因素。
研究设计与样本
- 报告37例接受自体CD19 CAR-T细胞治疗的儿童及年轻成人B细胞急性淋巴细胞白血病患者的长期结局。
主要发现
- 完全缓解率86%,其中71%为PCR MRD阴性、14%为流式MRD阴性、14%为PCR MRD阳性。
- 26例患者后续接受造血干细胞移植。
- 11例患者出现CD19阳性复发(8例移植后、3例未移植),1例出现CD19阴性复发,所有复发事件均发生在细胞治疗后两年内。
- 中位随访3年,中位无事件生存17个月,中位总生存未达到,3年无事件生存率41%、总生存率56%。
- 淋巴清除前骨髓原始细胞>5%的患者无事件生存较差;第28天PCR MRD阳性的所有患者均在CAR-T细胞治疗后复发。
关键数值与推荐
- 既往造血干细胞移植对结局无显著影响,但达到缓解后接受巩固性移植改善了长期结果。
临床怎么用
- 淋巴清除前疾病负荷和CAR-T细胞治疗后分子MRD阴性是长期结局的预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD28-based CD19 chimaeric antigen receptor-modified (CAR-)Tcells were recently FDA-approved for adult acute lymphoblastic leukaemia (ALL). We report long-term outcome of 37 children and young adults treated with autologous CD19 CAR-T cells. The complete remission rate was 86%, of which 71% were polymerase chain reaction (PCR) minimal residual disease (MRD)-negative, 14% were MRD-negative by flow cytometry, and 14% were PCR MRD-positive. 26 patients proceeded to subsequent haematopoietic stem cell transplant (HSCT). 11 patients had a CD19-postive relapse (eight post HSCT and three without) and one had a CD19-negative relapse. All relapse events occurred within two years from cell therapy. With a median follow-up of three years, the median event-free survival (EFS) is 17 months and the median overall survival (OS) is not reached. The three-year EFS is 41% and OS is 56%. Patients with >5% blasts in the bone marrow prior to lymphodepletion had an inferior EFS. All patients with a PCR MRD-positive result at day 28 had relapsed after CAR-T-cell therapy. A prior HSCT did not significantly affect outcome, but a consolidative transplant after achieving remission improved long-term results. Overall, prelymphodepletion disease burden and molecular MRD negativity following CAR-T cells are predictors of long-term outcome following CD19 CAR-T-cell therapy for ALL.
引用
- Jacoby E, Bielorai B, Hutt D, et al. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia. Br J Haematol. 2022. PMID: 35224724. doi:10.1111/bjh.18105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。